ClinicalTrials.gg
CompletedNCT01649427SpartacusUpdated Jun 17, 2019Results posted

Comparison of a Tacrolimus Hexal® Based Regimen Versus a Prograf® Based Regimen in de Novo Renal Transplant Recipients

A Phase 4 interventional study of Prograf and Tacrolimus Hexal in Pharmacokinetics Study in de Novo Kidney Transplantation, sponsored by Novartis Pharmaceuticals. Completed at 5 sites in Germany. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2019-06-17.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
73
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing tacrolimus in Graft vs Host Disease — 3 open to participants now, 4 under way, none of them phase 3. Tacrolimus · Graft vs Host Disease.

Enrollment
5th of 32
73 · median 34
Started
2012
with 2 others
Phase 4
3 of 36
none open now
Registered
24th of 36
by date
Lead sponsor
2 of 36
Novartis Pharmaceuticals

Among the 36 studies testing tacrolimus in Graft vs Host Disease, this one is the 5th largest by enrollment of the 32 interventional ones that give a count, is one of 3 that started in 2012, is one of 3 in phase 4, and was the 24th registered.

Graft vs Host Disease

804 studies on the registry are indexed under Graft vs Host Disease; 149 are open to participants now.

Browse Graft vs Host Disease studies →

Open to participants now

3 of the 36 studies testing tacrolimus in Graft vs Host Disease are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About tacrolimus

Tacrolimus: first FDA approval 1994 (PROGRAF), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 103 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 42 (41%) stop at 75 or younger; 42 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing tacrolimus in Graft vs Host Disease, or all of them as a file.
02

Study summary

The purpose of this study was to investigate if Tacrolimus Hexal® has similar pharmacokinetic properties compared to Prograf® in de novo renal transplant patients and whether the comparable exposure resulted in similar renal function.

Read the detailed description

In Phase II of this study there was a high patient drop-out rate and an associated long recruitment timespan. Eighty-one patients were recruited to Phase I and only 45 of the required 54 patients were available for PK analysis. To complete Phase II, 245 (in addition to 81) patients were to be required to achieve calculated sample size. Therefore the protocol was amended to stop recruitment and analyze Phase I patient data of CERL080ADE27 (PK-Phase I). Patients that were still ongoing were scheduled for an end of study (EOS) visit. During this visit patients were informed by the investigator about the end of study and advised about further treatment course.

03

Conditions studied

  • Pharmacokinetics Study in de Novo Kidney Transplantation

Browse trials for

Keywords

  • Pharmacokinetics Study
  • Tacroliums
  • GFR
  • kidney
  • transplant rejection
  • allograft rejection
  • xenograft rejection
  • host vs graft disease
  • renal transplant
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

primary or sec. kidney transplanted patiens, written consent, cold ischemia \< 24 h

Exclusion criteria

Exclusion:

multi organ, immunological risc pts., PRA >20%, Antibodys against HLA-type of donor organ, against Tacro or MMF,

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
73 participants (actual)

Study arms

  • Experimental
    Prograf

    Control therapy: one capsule containing 0.5 mg, 1mg or 5mg Prograf®, one tablet containing 180mg or 360mg Myfortic®, corticosteroids and one vial containing 20mg lyophilisate Simulect®

    Drug: Prograf

  • Experimental
    Tacroliums Hexal

    Investigational therapy: one capsule containing 0.5mg, 1mg or 5mg Tacrolimus Hexal®, one tablet containing 180mg or 360mg Myfortic®, corticosteroids and one vial containing 20mg lyophilisate Simulect®

    Drug: Tacrolimus Hexal

Interventions

  • Prograf® capsules were supplied as capsules of 0.5 mg, 1 mg and 1.5 mg dose strengths.

  • DrugTacrolimus Hexal

    Tacrolimus Hexal® capsules were supplied to the investigators at dose strengths of 0.5 mg, 1 mg and 1.5 mg.

06

What researchers measure

Primary outcomes

  1. ANCOVA Model for Change in Nankivell GFR (mL/Min) at Month 6, Without Replacement of Missing Values (Full Analysis Set)

    Change in Nankivell glomerular filtration rate (GFR) from baseline to 6 months Glomerular Filtration Rate (GFR): The GFR is the best clinical estimate of renal function in health and disease, and correlates well with the clinical severity of renal function disturbances. Several studies have shown that in patients with progressive renal disease, GFR declines or reciprocal serum creatinine levels elevate linearly over time in a predictable manner. With the help of the serum creatinine values, the GFR was calculated via Nankivell formula.

    Time frame: baseline to month 6

  2. ANOVA for Dose-normalized Tacrolimus 12-h-AUC (h/103*L) at Month 1

    Compares the PK of Tacrolimus Hexal® assessed by the ratio of the AUC0-12h over one month period post transplantation vs. Prograf® in renal transplant patients

    Time frame: end of month 1

Secondary outcomes

  1. The Incidence of Biopsy-proven Acute Rejection (BPAR), Graft Loss and Death Until Month 12 (Full Analysis Set) (Full Analysis Set)

    The key secondary objective was to assess the incidence of individual endpoints BPAR, graft loss and death until month 6 post-transplantation.

    Time frame: baseline to month 12

  2. ANCOVA Model for Change in CKD-EPI GFR (Chronic Kidney Disease Epidemiology Collaboration Glomerular Filtration Rate) at Month 6 Post-transplantation

    ANCOVA model for change in CKD-EPI Glomerular Filtration Rate (GFR)\[ml/min\] without replacement of missing values

    Time frame: baseline to Month 6

  3. ANCOVA Model for Change in MDRD GFR (ml/Min) at Month 6, Without Replacement of Missing Values

    MDRD GFR

    Time frame: least square (LS) mean change from baseline to Month 6

  4. ANCOVA Model for Change in Cockcroft-Gault GFR (ml/Min) at Month 6, Without Replacement of Missing Values

    change in Cockcroft-Gault GFR

    Time frame: least square (LS) mean change from baseline to Month 6

07

Results

Posted Jun 17, 2019
Limitations and caveats
1 patient was randomized to Prograf but didn't get treatment and was excluded from efficacy analyses but kept for safety reporting. Phase 2 was not started due to high drop-out rate. 73 enrolled; 43 of the planned 54 were available for PK analysis

Participant flow

81 patients were randomized, but only 73 were assigned drug. 1 patient who was excluded from efficacy analyses, was randomized to Prograf but did not receive treatment but kept for safety reporting. 74 patients were used for safety analysis while only 73 were available for efficacy analysis

Participant flow — Overall Study
MilestoneTacrolimus Hexal®Prograf®
Started3538
Completed2426
Not completed1112
Withdrew: Adverse event11
Withdrew: Withdrawal by subject87
Withdrew: Lost to follow-up01
Withdrew: Graft loss01
Withdrew: Surgical problems during nephrectomy22

Outcome measures

PrimaryANCOVA Model for Change in Nankivell GFR (mL/Min) at Month 6, Without Replacement of Missing Values (Full Analysis Set)

Change in Nankivell glomerular filtration rate (GFR) from baseline to 6 months Glomerular Filtration Rate (GFR): The GFR is the best clinical estimate of renal function in health and disease, and correlates well with the clinical severity of renal function disturbances. Several studies have shown that in patients with progressive renal disease, GFR declines or reciprocal serum creatinine levels elevate linearly over time in a predictable manner. With the help of the serum creatinine values, the GFR was calculated via Nankivell formula.

Time frame:
baseline to month 6
Reported as:
Least squares mean · mL/min
ANCOVA Model for Change in Nankivell GFR (mL/Min) at Month 6, Without Replacement of Missing Values (Full Analysis Set)
mL/minTacrolimus Hexal®Prograf®
ANCOVA Model for Change in Nankivell GFR (mL/Min) at Month 6, Without Replacement of Missing Values (Full Analysis Set)47.65 ± 20.2438.60 ± 18.83
Statistical analysis
  • Tacrolimus Hexal® vs Prograf® · ANCOVA · p = 0.0003
SecondaryThe Incidence of Biopsy-proven Acute Rejection (BPAR), Graft Loss and Death Until Month 12 (Full Analysis Set) (Full Analysis Set)

The key secondary objective was to assess the incidence of individual endpoints BPAR, graft loss and death until month 6 post-transplantation.

Time frame:
baseline to month 12
Reported as:
Number · Incidences
The Incidence of Biopsy-proven Acute Rejection (BPAR), Graft Loss and Death Until Month 12 (Full Analysis Set) (Full Analysis Set)
IncidencesTacrolimus Hexal®Prograf®
Biopsy proven acute rejection (BPAR)2 (0.70 to 19.16)3 (1.66 to 21.38)
Graft loss0 (0.00 to 10.00)1 (0.07 to 13.81)
Death0 (0.00 to 10.00)1 (0.07 to 13.81)
Composite: BPAR, graft loss or death2 (0.70 to 19.16)4 (2.94 to 24.80)
SecondaryANCOVA Model for Change in CKD-EPI GFR (Chronic Kidney Disease Epidemiology Collaboration Glomerular Filtration Rate) at Month 6 Post-transplantation

ANCOVA model for change in CKD-EPI Glomerular Filtration Rate (GFR)\[ml/min\] without replacement of missing values

Time frame:
baseline to Month 6
Reported as:
Least squares mean · mL/min
ANCOVA Model for Change in CKD-EPI GFR (Chronic Kidney Disease Epidemiology Collaboration Glomerular Filtration Rate) at Month 6 Post-transplantation
mL/minTacrolimus Hexal®Prograf®
ANCOVA Model for Change in CKD-EPI GFR (Chronic Kidney Disease Epidemiology Collaboration Glomerular Filtration Rate) at Month 6 Post-transplantation48.33 ± 3.8439.77 ± 4.61
PrimaryANOVA for Dose-normalized Tacrolimus 12-h-AUC (h/103*L) at Month 1

Compares the PK of Tacrolimus Hexal® assessed by the ratio of the AUC0-12h over one month period post transplantation vs. Prograf® in renal transplant patients

Time frame:
end of month 1
Reported as:
Least squares mean · h/10^3*L
ANOVA for Dose-normalized Tacrolimus 12-h-AUC (h/103*L) at Month 1
h/10^3*LTacrolimus Hexal®Prograf®
Adjusted, log-transformed Estimates (ANOVA)2.944 (2.783 to 3.105)3.020 (2.811 to 3.228)
Adjusted, back-transformed Estimates (ANOVA)18.991 (16.163 to 22.314)20.484 (16.630 to 25.231)
SecondaryANCOVA Model for Change in MDRD GFR (ml/Min) at Month 6, Without Replacement of Missing Values

MDRD GFR

Time frame:
least square (LS) mean change from baseline to Month 6
Reported as:
Least squares mean · (ml/min)
ANCOVA Model for Change in MDRD GFR (ml/Min) at Month 6, Without Replacement of Missing Values
(ml/min)Tacrolimus Hexal®Prograf®
ANCOVA Model for Change in MDRD GFR (ml/Min) at Month 6, Without Replacement of Missing Values46.20 (37.62 to 54.79)38.52 (28.64 to 48.41)
SecondaryANCOVA Model for Change in Cockcroft-Gault GFR (ml/Min) at Month 6, Without Replacement of Missing Values

change in Cockcroft-Gault GFR

Time frame:
least square (LS) mean change from baseline to Month 6
Reported as:
Least squares mean · (ml/min)
ANCOVA Model for Change in Cockcroft-Gault GFR (ml/Min) at Month 6, Without Replacement of Missing Values
(ml/min)Tacrolimus Hexal®Prograf®
ANCOVA Model for Change in Cockcroft-Gault GFR (ml/Min) at Month 6, Without Replacement of Missing Values60.45 (52.48 to 68.41)46.45 (36.89 to 56.02)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tacrolimus Hexal—19/35 (54.3%)34/35 (97.1%)
Prograf—17/39 (43.6%)38/39 (97.4%)
Most frequent serious events
Showing 10 of 58
Most frequent serious events
EventTacrolimus HexalPrograf
URINARY TRACT INFECTIONInfections and infestations4/354/39
COMPLICATIONS OF TRANSPLANTED KIDNEYInjury, poisoning and procedural complications4/353/39
BLOOD CREATININE INCREASEDInvestigations4/351/39
DIARRHOEAGastrointestinal disorders3/350/39
ACUTE KIDNEY INJURYRenal and urinary disorders3/350/39
PROTEINURIARenal and urinary disorders3/350/39
KIDNEY TRANSPLANT REJECTIONImmune system disorders2/352/39
UROSEPSISInfections and infestations2/350/39
INCISIONAL HERNIAInjury, poisoning and procedural complications2/350/39
FOCAL SEGMENTAL GLOMERULOSCLEROSISRenal and urinary disorders2/350/39
Most frequent other events
Showing 10 of 66
Most frequent other events
EventTacrolimus HexalPrograf
HYPERTENSIONVascular disorders12/3520/39
WOUND COMPLICATIONInjury, poisoning and procedural complications16/3519/39
URINARY TRACT INFECTIONInfections and infestations6/3516/39
COMPLICATIONS OF TRANSPLANTED KIDNEYInjury, poisoning and procedural complications5/3511/39
HYPERKALAEMIAMetabolism and nutrition disorders9/359/39
HYPERURICAEMIAMetabolism and nutrition disorders3/359/39
ANAEMIABlood and lymphatic system disorders4/357/39
LEUKOPENIABlood and lymphatic system disorders3/357/39
OEDEMA PERIPHERALGeneral disorders3/357/39
HYPOMAGNESAEMIAMetabolism and nutrition disorders5/357/39

Baseline characteristics

The Full Analysis Set (FAS) consisted of all patients in whom study treatment was assigned. Following the intent-to-treat principle, patients were analyzed according to the treatment they were assigned to at randomization

Age, Continuous
Age, Continuous(years)Tacrolimus Hexal®Prograf®Total
Mean47.9 ± 9.947.2 ± 11.847.5 ± 10.8
Sex: Female, Male
Sex: Female, Male(Participants)Tacrolimus Hexal®Prograf®Total
Female6915
Male292958
08

Study locations

5 sites
  • Novartis Investigative Site
    Berlin, 10098, Germany
  • Novartis Investigative Site
    Bochum, 44892, Germany
  • Novartis Investigative Site
    Duesseldorf, 40225, Germany
  • Novartis Investigative Site
    Kaiserslautern, 67655, Germany
  • Novartis Investigative Site
    Koeln-Merheim, 51109, Germany
09

References and documents

Individual participant data

Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2012 to primary completion in Aug 2015, 34 months.

Results were first posted in Jun 2019, 3 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2012
First posted
Jul 25, 2012
StartActual
Oct 17, 2012
Primary completionActual
Aug 20, 2015
CompletionActual
Aug 20, 2015
Results first posted
Jun 17, 2019
Last update
Jun 17, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01649427
Responsible party
Sponsor
First posted
Jul 25, 2012
Start date
Oct 17, 2012
Primary completion
Aug 20, 2015
Completion
Aug 20, 2015
Results posted
Jun 17, 2019
Last update
Jun 17, 2019

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tacrolimus

Start the discussion